The selective tyrosine kinase inhibitor imatinib has been shown to inhibit the Abl tyrosine kinases Bcr-Abl, c-Abl, v-Abl and Ablrelated gene (ARG) as well as platelet-derived growth factor receptor (PDGF)-R alpha and beta and the receptor for human stem cell factor (SCF), c-kit. 1 Side effects are mostly moderate; however, a dose-dependent hematologic toxicity affecting all hematopoietic lineages is observed clinically. 2, 3 Based on the known functions of c-Abl, c-kit and PDGF-R in the hematopoietic system, one could speculate on potential hematotoxic side effects particularly after long-term exposure to the drug. In a recent study, we have shown that imatinib affected the proliferation of growth factor stimulated hematopoietic progenitor cells in vitro in a dose-dependent manner. The antiproliferative effect of imatinib was substantially greater, as compared to the withdrawal of stem cell factor or functional inhibition of c-kit at all dose levels tested. These data suggest a significant inhibitory effect of imatinib on normal CD34
þ progenitor cells that is largely independent of c-kit signaling. 4 Based on this finding, the aim of this study was to investigate the molecular effects of imatinib and c-kit inhibition on the gene expression profile of normal human CD34 þ cells in vitro.
CD34
þ cells from fresh leukapheresis products of healthy donors (n ¼ 4) were selected with informed consent using a Midi-MACS CD34 Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD34 þ cells (purity: between 92% and 95%) were cultured in 24-well plates, containing serum-free medium (SFM) supplemented with human SCF (100 ng/ml), human Flt-3 ligand (100 ng/ml), human thrombopoietin (50 ng/ml), human interleukin 3 (IL-3), human IL-6 (both 20 ng/ml; all from CellSystems, St Kartharinen, Germany) and granulocyte colony-stimulating factor (G-CSF; 20 ng/ml; Amgen, Munich, Germany), 5 for 24 h either untreated, with imatinib (at 1.25 mmol) or with 1 mg/ml of a c-kit-R monoclonal antibody (Sigma-Aldrich, St Louis, MO, USA), respectively.
Total RNA was extracted using TRIzol (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol with minor modifications. In order to assure that the gene expression measured by microarray assay was not affected by degradation of the RNA extracted from the clones, we used the BioanalyzerSystem (Agilent Technologies, Waldbronn, Germany) to evaluate the quality of the RNA. The detailed protocol for the sample preparation and microarray processing is available from Affymetrix Inc. (Santa Clara, CA, USA). As a result of the limited number of cells and the low RNA content, a double in vitro transcription technique ('nanogram scale assay') was used, as described previously. 6 In all 50 ng of purified RNA was reverse transcribed by Superscript II reverse transcriptase (Invitrogen) using T7-(dT)24 primer containing a T7 RNA polymerase promoter. After synthesis of the second cDNA strand, this product was used in an in vitro transcription reaction to generate complementary cRNA. This cRNA was used for a second round of in vitro transcription for synthesis of the biotinylated cRNA. In all 15 mm of fragmented cRNA was hybridized to a HG-U133A microarray (Affymetrix). Data analysis was performed with the GeneSpring software version 4.2 (Silicon Genetics Inc., San Carlos, CA, USA). Data were normalized first by 'each sample to itself' (making the median of all measurements within one sample to 1) and secondly by 'each gene to itself' (making the median of all measurements of one gene within several samples to 1). To eliminate changes within the range of background noise and to select the most differentially expressed genes, upregulated genes were required to be called 'present' by the Affymetrix data-analysis. For differential gene expression a minimum of two-fold change was required. Hierarchical clustering analysis with Spearman's confidence correlation was used to identify gene clusters. The separation ratio was set at 0.5. In addition to the statistical restrictions for data analysis as described, for a first analysis we required that genes that are differentially expressed in imatinib-treated cells as compared to untreated cells passed the restrictions as defined in all (four of four) paired samples analyzed. A 42-fold upregulation of five genes in imatinib-treated cells was detected (as summarized in Table 1 ), whereas five genes showed a downregulation in these cells (Table 1, Figure 1a) . The application of less stringent restrictions to the data analysis (expression changes were required to be present in at least three of four paired samples) resulted in 33 upregulated and 13 downregulated genes, respectively (Figure 1b) . Interestingly, no differential gene expression in all four paired samples studied was found when CD34 þ cells treated with c-kit inhibition by a functionally c-kit blocking monoclonal antibody were compared to untreated cells (Figure 1a) . However, when imatinib-treated cells were compared to c-kit inhibited cells, we found one gene differentially upregulated (heat shock protein 70, NM_002155) and one gene downregulated (Retinol dehydrogenase homolog, NM_005771). The complete set of microarray data will be available on publication at: http://knm1.ibe.med.uni-muenchen. de/~hellenbrecht/WKH/index.htm.
To confirm the expression data from the microarray studies, we analyzed the expression of two selected, differentially regulated genes in a control set of two different individual samples of CD34 þ cells that were again expanded either without imatinib, with 1.25 mmol imatinib or with the c-kit inhibitory monoclonal antibody (1 mg/ml) by real-time quantitative polymerase chain reaction (RTQ-PCR). The results were normalized to the expression of GAPDH in each of the samples. We found a 42-fold upregulation of cyclin G2 expression in imatinib treated cells as compared to untreated cells in both samples studied (3.0 and 5.9-fold), but also in c-kit inhibited as compared to untreated cells (3.3 and 3.7-fold). A 42-fold cytochrome-p450-1B1 overexpression was confirmed in both imatinib-treated specimen (2.1 and 3.3-fold), but was also observed in one out of two samples with the c-kit inhibited cells (3.0-and 1.8-fold). Thus, differential gene expression in imatinib as compared to untreated cells observed by oligonucleotide microarray analysis was confirmed by RTQ-PCR for the selected genes. However, RTQ-PCR also revealed an overexpression of the two genes investigated in c-kit inhibited as compared to untreated cells suggesting a higher sensitivity of the assay as compared to microarray analysis at least under the stringent restrictions used for this study.
These data further support the hypothesis, that the inhibitory effect induced by imatinib extends beyond the effect induced by inhibition of c-kit alone. The genes that were differentially up-or down-regulated in imatinib-treated cells compared to untreated cells could be assigned to different functional groups (Table 1) . Among others, we found genes involved in cell cycle regulation and regulation of proliferation. One representative example, that could potentially explain the growth inhibitory effect on hematopoietic progenitor cells is cyclin G2 (over-expressed under imatinib). Cyclin G2 is mostly expressed during S-phase and its regulation has been shown to be strictly cell-cycle dependent. Expression of cyclin G2 is upregulated if cells undergo cell-cycle arrest or apoptosis due to inhibitory stimuli.
Furthermore, ectopic expression of cyclin G2 induces G1/S-phase cell cycle arrest, an effect that is mediated by interaction with phosphatase 2A. 7 Moreover, it has been shown that in murine B cells responding to growth inhibitory stimuli, cyclin G2 represents a key negative regulator of cell cycle progression. 8 Our results suggest that imatinib-mediated effects are accompanied by characteristic changes in the gene expression profile of normal CD34 þ cells in vitro, which are largely c-kit independent. In contrast to our study, Neumann et al 9 found no evidence for the influence of imatinib on the gene expression patterns in Bcr-Abl negative CD34
þ cells of patients with BcrAbl positve CML in major molecular remission in vivo. We, therefore, hypothesized that the in vitro cytokine stimulation by the growth factor cocktail used in this study was one of the reasons for the increased susceptibility of the normal cells to imatinib. Ongoing studies will be aimed at the characterization and functional analysis of cyclin G2 in order to better define its functional importance in imatinib-treated and untreated normal human hematopoietic progenitor cells in vitro and in vivo. These genes were selected because their expression was up (+) F or downregulated (À) X2-fold in four of four treated samples as compared to untreated CD34 + cells. Access indicates GenBank accession number. Expression values are based on microarray data. Scheme of the number of differentially regulated genes between the no treatment, imatinib-treated or anti-c-kit-treated group in four out of four (a) and three out of four (b) samples of normal CD34 þ cells studied.
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